R&D Archives -

News/ News/ News/ Patients/ R&D

FDA sets out its thinking on protecting children in clinical trials

Phil Taylor child safety, clinical research, clinical trials, ethics, fda, paediatrics, R&D 0 Comment

The FDA has published draft guidance giving its position on the ethical reasons for including children in clinical

FDA sets out its thinking on protecting children in clinical trials

https://pharmaphorum.com/news/fda-sets-out-its-thinking-on-protecting-children-in-clinical-trials/

News/ News/ News/ R&D/ Sales and Marketing

Revamped Novartis highlights top R&D programmes at management update

Phil Taylor iptacopan, Kisqali, Novartis, Pluvicto, R&D, remibrutinib, Sales and Marketing, Scemblix, strategy 0 Comment

With a reorganisation of Novartis now nearing completion, the Swiss pharma group is laying out its plans for

Revamped Novartis highlights top R&D programmes at management update

https://pharmaphorum.com/news/revamped-novartis-highlights-top-rd-programmes-at-management-update/

News/ News/ News/ Oncology/ R&D

First human data backs Calibr/AbbVie’s “switchable” CAR-T therapy

Phil Taylor AbbVie, Calibr, CAR-T therapy, immuno-oncology, Oncology, R&D 0 Comment

California biotech Calibr and partner AbbVie have reported the first clinical data on a new CAR-T technology, which

First human data backs Calibr/AbbVie’s “switchable” CAR-T therapy

https://pharmaphorum.com/news/first-human-data-backs-calibr-abbvies-switchable-car-t-therapy/

News/ News/ R&D

Novartis lines up Merck exec to replace R&D leader Jay Bradner

Phil Taylor Fiona Marshall, Jay Bradner, Merck & Co, Novartis, R&D, senior management 0 Comment

Jay Bradner, president of the Novartis Institutes for Biomedical Research (NIBR), is retiring from the position after seven

Novartis lines up Merck exec to replace R&D leader Jay Bradner

https://pharmaphorum.com/news/novartis-lines-up-merck-exec-to-replace-rd-leader-jay-bradner/

News/ News/ R&D

Karuna Therapeutics scores phase 3 win for schizophrenia therapy KarXT

Eloise McLennan clinical trial, Karuna Therapeutics, pharma, R&D, schizophreina 0 Comment

Karuna Therapeutics has unveiled positive topline results from its phase 3 EMERGENT-2 trial evaluating the efficacy, safety, and

Karuna Therapeutics scores phase 3 win for schizophrenia therapy KarXT

https://pharmaphorum.com/news/karuna-therapeutics-scores-phase-3-win-for-schizophrenia-therapy-karxt/

News/ News/ News/ R&D/ Sales and Marketing

Pfizer heading for purple patch of in-house product launches

Phil Taylor Pfizer, pipeline, R&D, Sales and Marketing 0 Comment

With record-breaking revenues and profits accruing on the back of its COVID-19 products, Pfizer is planning a big

Pfizer heading for purple patch of in-house product launches

https://pharmaphorum.com/news/pfizer-heading-for-purple-patch-of-in-house-product-launches/

Digital/ News/ News/ News/ R&D

Despite ban, Martin Shkreli can’t seem to kick the pharma habit

Phil Taylor Blockchain, cryptocurrency, digital, drug discovery, Druglike, Martin Shkreli, R&D 0 Comment

Given that Martin Shkreli has a lifetime restraining order preventing him from working in the pharma industry, it

Despite ban, Martin Shkreli can’t seem to kick the pharma habit

https://pharmaphorum.com/news/despite-ban-martin-shkreli-cant-seem-to-kick-the-pharma-habit/

News/ News/ R&D

NewAmsterdam goes public to advance drug in abandoned class

Phil Taylor cardiovascular, cholesterol, Merck & Co, NewAmsterdam Pharma, obicetrapib, R&D 0 Comment

NewAmsterdam Pharma has charted out a route to a Nasdaq listing by merging with black cheque company Frazier

NewAmsterdam goes public to advance drug in abandoned class

https://pharmaphorum.com/news/newamsterdam-goes-public-to-advance-drug-in-abandoned-class/

News/ News/ R&D

Teva poaches Vertex exec as new head of R&D

Phil Taylor R&D, senior management, Teva, Vertex Pharma 0 Comment

Teva chief executive Kare Schultz has lined up the appointment he wants to revitalise the company’s R&D operations,

Teva poaches Vertex exec as new head of R&D

https://pharmaphorum.com/news/teva-poaches-vertex-exec-as-new-head-of-rd/

Trending

R&D

Login